Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Draadje OT, bijzaken & geleuter in de marge!
Volgen
PIPER #ASGCT15 Day2 takeaways $BIIB $AAVL $QURE $BLCM $CLLS $SGMO $LBIO $BLUE "Gene Editing Safe, So Far"t.co/Q5nXloGyCG
PIPER: During the final 2 days of the ASGCT annual meeting, we continue to be impressed by the speed at which the gene therapy and gene editing field continues to evolve and iterate. In a particularly well attended presentation, additional academic data from the ongoing St. Jude's / UCL trial for gene therapy in hemophilia B was presented. Overall, we highlight several of our key takeaways from the conference, with companies including BIIB, AAVL, QURE, BLCM, CLLS, LBIO, BMRN and BLUE all with exposure. We will address many of these topics and findings at our GenomeRx Symposium this week in NYC. • Hemophilia B Data Continues To Impress: Data from the ongoing trial being conducted at St. Jude's / UCL was presented disclosing additional FIX expression data in treated patients, one of which goes beyond 5 years with many patients now 3-4 years post infusion. Patients continue to see robust and durable FIX expression (2-7% in high dose) with seemingly no sign of waning, in contrast to the recent NEJM paper describing a waning of effect after 3 years in LCA patients. This continues to highlight the curative potential of liver-directed gene therapy. Immunosuppression remains an active topic of debate, and we note that 2 additional patients in this trial have been treated with a vector preparation designed to remove empty capsids, with no sign of immune response seen post infusion. In addition, work with modified FVIII variants for hemophilia A was presented (for additional detail on the challenges of FVIII and preliminary work in new FVIII variants, see our December deep dive) and is expected to enter the clinic in 2016. We note that BMRN has licensed technology from UCL and is entering the clinic imminently and we look forward to further updates and details on these approaches. Interestingly, the hemophilia A gene therapy preclinical program presented by UCL used AAV5, which could give BMRN freedom to operate if it kept this vector. It also utilized a B-domain deleted construct with partial-add back of a site which seems to meaningfully increase Factor production. • Process improvements will come in all forms: One factor which we have underestimated is the ongoing improvement to the manufacturing processes for viral vectors and adoptive immunotherapy. Presentations at ASGCT focused on details all the way down to the buffer selected. While vector selection and tropism are obvious determinants of clinical success, we are also starting to appreciate that gains in manufacturing may be equally impactful in furthering the clinical profiles of these products. • Key Advancements Drive The Field Forward: We believe several factors are contributing to the rapid pace of innovation: advances in genetics and affordable gene sequencing (which will also help identify patients for trials and therapies), creation of new and improved animal models and better disease pathway elucidation, biology techniques like cell-sorting and electroporation, and academic centers pivoting to be more commercial and disease oriented (including advanced manufacturing facilities). Companies also continue to learn from each other with respect to key variables, including systemic administration and immune suppression, dosage, vector serotype and evolution, etc.. All of this will allow earlier de-risking of clinical programs. We also believe the field has learned from prior setbacks and is moving forward thoughtfully and carefully. Which All Bodes Well For The Commercial And Investment Potential: As gene therapy continues to evolve as a platform, we therefore expect that access to capital will remain robust and that return on investment will remain favorable. While we expect an iterative path with both successes and failures along the way, we note that investors are becoming more comfortable with gene therapy and increasingly understand which variables are driving results, evaluating both positive and negative trials on their own considerations. Overall, gene therapy has truly begun to unlock the vast orphan disease market as well as make inroads in larger markets, and the potential benefits of gene therapy are broadly applicable.bridgetunnelinvestor.freeforums.net/t...
Suntrust: ASGCT Days 3&4; Bright Future for Hemophilia, CAR T Activity Remains Impressive What's Incremental. The final days of the ASGCT meeting featured updates from a Phase I trial of AAV-based gene therapy for hemophilia B (conducted by UCL/St. Jude). As BMRN in-licensed gene therapy technologies for hemophilia A from these academic centers, we believe the ~5 year persistence of hemophilia B gene therapy in this updated Phase I trial bodes well for BMRN's BMN 270 (data in Q4 or Q1 2016) - currently upside to our estimates. We like BMRN ahead of BMN 111 results in achondroplasia (end-Q2) and other H2 catalysts. In addition, CAR T cells continue to impress on the ALL efficacy front. Updates from a University College London/St. Jude's clinical trial in hemophilia B bode well for BMRN's program. Dr. Amit Nathwani (UCL, London, UK) discussed a Phase I study of AAV8-induced expression of clotting Factor IX (FIX) in 10 patients with hemophilia B (longer follow up to data previously published in November 2014 in the New England Journal of Medicine, NEJM). In line with previous disclosure, all patients achieved 1-5% FIX expression post gene therapy, sufficient to enable significant reduction in bleeds associated with hemophilia B. A key observation for the outlook of gene therapy approaches has been immunogenicity elicited by the AAV8 capsid, resulting in liver toxicity as evidenced by liver enzyme (ALT) elevations, and reduction in FIX levels post treatment. Management with immunosuppressants (i.e. prednisone) in patient 5, as soon as ALT elevations occurred, resulted in a less dramatic decrease in FIX levels. In addition, preventative prednisone dosing in patients 6-10 precluded ALT increases and loss of gene therapy-induced FIX production. Key updates to the NEJM article from patients 5-9 illustrate maintained FIX production at years 4, 4.5, 3, 2.5, and 2 (versus 3, 3.5, 2, 2.5, and 1.5 in the NEJM article, respectively). The sustained FIX production was associated with reduced need for FIX prophylaxis and significant improvement in the quality of life. In addition, Dr.Nathwani noted that in non-human primates, a single administration of FIX gene therapy is associated with persistence at ~10 years follow-up. We note BMRN's BMN 270 program for hemophilia A (to enter the clinic in the summer) is based on technology licensed from UCL and St. Jude's Research Hospital, and believe the durability of response seen in the hemophilia B study bodes well for the outlook of BMN 270 (albeit a larger gene for hemophilia A). Two presentations discussed approaches to overcome challenges to designing a successful hemophilia A gene therapy. Per Dr. Nathwani's presentation, several challenges render hemophilia more difficult to address compared to hemophilia A. A second presentation was delivered by Dr. Denise Sabatino (Children's Hospital of Philadelphia, collaboration with ONCE) and fully dedicated to this topic. First, the defective protein in hemophilia A, factor VIII (FVIII), is encoded by a large gene, which exceeds the packaging capacity of AAV vectors. Thus, different investigator groups have generated truncation constructs of FVIII that appear to successfully recapitulate FVIII activity in animal models of disease (this also appears to be the case with BMRN's FVIII construct entailed by BMN 270, per data presented at the company's R&D Day in December 2014). Second, compared to proteins of the same size, the production of FVIII is highly inefficient in animal/human cells or in vivo. Truncation of FVIII appears to also influence production (as the deleted portion likely include genetic information for ineffective FVIII production), as well as the stability and the potency of FVIII. Thus, we believe that different optimization techniques for FVIII truncation are likely to differentiate the multiple programs in development. A presentation of CD19-28z CAR T's highlights the efficacy of this approach in adult ALL, questions remain on toxicity. Updated results from a Phase I study of JUNO's (not covered) CD19-28 CAR T cells were presented by Dr. Jae Park (Memorial Sloan Kettering Cancer Center) as a "top abstract". As of 03/03/15, 35 adult patients with highly refractory acute lymphoblastic leukemia (ALL) had been treated with CD19-28z CAR T cells (34 patients evaluable for a response with >1 month follow up). 30 (88%) patients achieved a complete response (CR), while 24 (83%) out of 29 patients evaluated for minimal residual disease achieved negativity. These data compare very well with historical trials, where 18-20% patients achieved a CR. The median overall survival was 8.5 months in all patients, and 10.5 months in the responders. T cells persisted 1-3 months following infusion. The main concern related to CAR T therapies appears to be safety, including cytokine release syndrome (CRS, fever, hypotension, respiratory insufficiency) and neurological toxicities (delirium, encephalopathy, seizures). 7 (20%) of the patients experienced CRS, and 10 (29%) experienced neurotoxicity (not correlated to CRS). CRS was managed with IL-6 inhibitors while neurological toxicities were associated with disease burden and were reversible. We view these data as exciting, given the very low historical rates of response in this aggressive blood cancer, and look towards future optimization/improved management of the adverse events associated with CAR T therapy.bridgetunnelinvestor.freeforums.net/t... mobile.twitter.com/captainfuture__
Uit Griekenland. Health: The challenge of the 21st century As the population of the earth increasingly "aging" raised questions about the sustainability of health systems. What are the new challenges they face and how technology can be a solution? Currently several efforts intensified in the direction of reducing the cost of research for the development of new drugs - which is currently estimated at an average of 2.5 billion. Dollars.A typical example is the debate has erupted on the case of Glybera, the first gene therapy approved in the western hemisphere. Essentially Glybera offers permanent cure rare disease lack lipoprotein lipase (LPLD) with patients suffering from the disease are prone to recurrent pancreatitis episodes. The problem; The cost of treatment, which reaches 780,000 euros for each patient. The Dutch company uniQure that created justify the price by referring to the high cost of research and stressing that the respect Glybera gene intervention that will bring permanent cure. Of course this should be emphasized that the lack of disease lipoprotein lipase (LPLD) relates only 150-200 patients in Europe, so the company addresses a very small audience, which should cover the cost of developing the drug.translate.google.com/translate?hl=en&...
Bluebird, Regulators Map Out Approval Plan For Gene Therapy One of gene therapy’s major unanswered questions is just what it’ll take to convince U.S. regulators to approve one of these treatments. With a gene therapy that’s already produced promising results in a few patients in clinical trials, Bluebird Bio has a chance to pave the way. And today it’s cut a deal with the FDA to figure out how to get that treatment to the regulatory finish line. Bluebird (NASDAQ: BLUE) said this morning that it’s come to an agreement with regulatory agencies both in the U.S. and in Europe on an approval path for LentiGlobin, its gene therapy for beta-thalassemia, a crippling blood disorder. The agreements map out potential approval on an accelerated basis for the therapy—based on less of a body of data than is typically required. If Bluebird were to succeed, it would have the chance to own the first gene therapy approved in the U.S., a major milestone for the field. Only Europe has an approved gene therapy, Glybera, from Uniqure (NASDAQ: QURE) for a rare metabolic disorder, and that product hasn’t been launched yet. Approval is still a ways away, of course. To this point, Bluebird has produced very promising data, but in just four patients. With past gene therapies falling short of expectations in clinical trials, a lot more proof is needed. And then there’s the question of how much LentiGlobin would cost (would it be paid for in one large, lump sum? On an annuity basis?). Nonetheless, Bluebird has an unusual opportunity in front of it. Here’s what the Cambridge, MA-based company needs to do to get LentiGlobin to market: In the U.S., Bluebird will have to run two additional trials, called HGB-207 and HGB-208. These are each 15-patient, open-label studies—not placebo-controlled, randomized trials. Adults and adolescents with beta-thalassemia will be enrolled in HGB-207, and children in HGB-208. Bluebird will track these patients’ results for two years, and the goal will be to free the subjects of the blood transfusions they normally require to prevent anemia for 12 months. Bluebird says that based on its talks with the FDA, data from these two studies and the two existing trials underway (known as Northstar and HGB-205), will form the basis for a regulatory filing. Northstar and HGB-205 are enrolling patients in the U.S. and Europe, respectively, with either beta-thalassemia or sickle cell disease. If LentiGlobin hits its goal, Bluebird believes it could seek accelerated approval, and conduct post-approval long-term follow up studies of these patients. In Europe, Bluebird has been working with the European Medicines Agency and others, and based on those discussions, believes that it can win conditional approval of LentiGlobin based on the data from HGB-205 and Northstar studies alone. That conditional nod could be converted to a full approval should Bluebird successfully complete HGB-207 and HGB-208, and obtain more long-term follow-up and post-approval monitoring data. This feedback brings us closer to achieving our vision of delivering one-time, potentially transformative gene therapy to patients,” Bluebird chief medical officer David Davidson said in a statement. Bluebird is holding a conference call this morning to discuss the news. Patients with beta-thalassemia inherit a faulty gene that codes for beta globin, a subunit of hemoglobin, the protein in red blood cells that carries oxygen. Without the ability to make hemoglobin, these patients get severe anemia and need frequent blood transfusions to survive. They also need iron chelation therapy to deal with the iron overload those transfusions cause; that buildup of iron often kills patients. About 15,000 people in the U.S. and Europe and 280,000 worldwide are estimated to be living with the disorder, and a majority of them have beta-thalassemia major, the severe form, according to Bluebird.www.xconomy.com/boston/2015/05/19/blu...
Sarepta Therapeutics Announces Plans to Submit Rolling NDA for Eteplirsen following Today’s Pre-NDA Meeting with the FDA - www.nasdaq.com/press-release/sarepta-...
Biotechnology Trends: What The Heck Are CAR-T And CRISPR? May 19, 2015 12:29 PM This blog won't attempt to do a deep dive into these emerging biotechnology trends. Frankly I'm still learning about them myself. As an alternative, I'll take the lead from a Quantum Physicist, Gemma Godfrey, and her refreshing TEDxWallStreet speech: How To Kiss. In short this blog will simply touch on the techniques and then put them in context. Seems like an appropriate first step to help investor's identify rather than avoid emerging opportunities. CRISPR ("clustered regularly interspaced short palindromic repeats") is a form of gene editing. This Wikipedia image is confusing enough to show that a blog on the science would not be helpful to most investors. CAR-T ("Chimeric Antigen Receptors") is also a form of gene manipulation which attempts to engineer a patient's own immune system (T-cells) to fight their cancer. Dr Renier Brentjens (Sloan Kettering Cancer Center) describes this type of adoptive cell transfer as "giving patients a living drug". Both of these approaches are high-risk, early-stage approaches that have numerous hurdles yet to overcome. However they are rapidly gaining momentum and endorsement in the medical community. Genomic alternation has been discussed for years as genomic sequencing has become a reality. Many view this in a very negative light, worrying the genetic equivalent of plastic surgery will become the norm. Consider a recent MIT Technology Review article well worth a read: Genome Surgery. I loved the title as it quickly framed the issue. Society has long accepted surgery as a medical option without reservation, even though cosmetic surgery is considered by some as questionable. The morality issues raised are not insignificant, but the potential benefits far outweigh them. Another article well worth reading is: Human Ingenuity Takes on Cancer's Darwinian Ways, published in the New York Times. This article draws a parallel between evolutionary aspects of cancer and immune cells. It also states: "scientists have treated some patients by extracting their immune cells and re-engineering them to fight tumors. Sometimes, the cancer cells themselves are used to develop a custom vaccine, immunizing a body against a destructive subset of itself." Sounds consistent with the National Institute of Health Precision Medicine Initiative to me. Analysts are actively publishing reports on the trends. Piper Jaffray issued a subscription-only report today: Gene Editing Primer: New Tools Emerging To Do Great Things. In this report they state: Simply put, gene editing platforms are genetic scissors which can cut DNA and lead to knockout or correction or insertion of genetic sequences. Progress is already being made deploying gene editing platforms to knock out: 1) the CCR5 receptor to treat HIV, 2) the BCL11a enhancer to treat hemoglobinopathies, and 3) T-cell receptors and other proteins to enable....enhanced CAT-T and TIL products. The value of precisely correcting DNA is immeasurable if accomplished with precision and control...while debate rages (in utero germline correction of disease), the platforms continue to evolve and improve in a direction where someday this should be feasible. Overall, we believe we are officially in an era of gene therapy 2.0 and the time has arrived for gene editing. Leerink published their insights on What's Next in Gene Therapyfrom the American Society of Gene & Cell Therapy (5/13-5/13) annual meeting. Their takeaways: There was significant interest in improving gene transfer technologies. There was a major focus on gene editing platforms, with a keen interest in differentiating the various approaches. Incremental color provided by the Dr Nathwani update on the hemophilia B rial at UCL can be interpreted positively for QURE and others. We view the presentation of regulatory expectations for gene and cell therapies as optimistic. In summary these approaches are a natural extension of genomic sequencing and have been anticipated for years. There are many obstacles and moral dilemmas still on the path to success. Yet the trends are clear: Genomic editing (aka surgery) is an exciting trend in biotechnology and well worth the effort to identify and invest in the best of breed companies leading the charge. Disclosure: The author is long KITE, JUNO, QURE, BMRN, PFE, BIIB, XON.seekingalpha.com/instablog/400846-mar... twitter.com/mchilberg
arGEN-X: la petite soeur surdouée d'Ablynx et Galapagos ? - mon analyse à lire: t.co/RiKnWexUQ8 mobile.twitter.com/logribel
ArGEN-X: Forging The Future Of Antibodiesseekingalpha.com/article/3243776-arge...
When your genome costs less than your iPhone: The beautiful, terrifying future of DNA sequencingwww.techrepublic.com/article/when-you...
Regels frustreren revolutie in farmacie June 12, 2015 Risicovrees en cententellerij zijn fnuikend voor farmaceutische innovaties, betogen de hoogleraren Van Deventer, Girbes en Singer. We staan aan de vooravond van grote innovaties op het gebied van medische behandelingen. Europa speelt een belangrijke rol bij de doorbraak van nieuwe medicijnen en de ontwikkeling van genen celtherapie. Helaas worden deze inspanningen gefrustreerd door hindernissen in de regelgeving. In plaats van het enorme potentieel van innoverende middelen in te zien, zijn regulerende autoriteiten, zorgverzekeraars en politici vooral bezorgd over de prijs van dergelijke vernieuwingen. De huidige restrictieve protocollen, die door verzekeraars worden afgedwongen voor het gebruik van anti-TNF bij chronische darmontstekingen, vormen een voorbeeld van de negatieve invloed van hún kostenbesparing op het potentiële heil dat de individuele patiënt hiervan mag verwachten. Het is gemakkelijk om de besparing uit te rekenen die het gevolg is van het niet beschikbaar stellen van een effectief medicijn. Maar het is veel minder eenvoudig om te bepalen wat de opbrengst is van het ziektevrij houden van een patiënt, en diens bijdrage aan de samenleving. Deze ‘opbrengst’ wordt door zorgverzekeraars genegeerd. Bijwerkingen Het afgeven van een licentie voor een nieuw te vergoeden medicijn kan nu soms langer dan tien jaar duren door uitgebreide regelgeving en overheidsbeleid dat de zorgkosten wil verlagen. Natuurlijk moeten nieuwe medicijnen getest worden voordat die op de markt worden gebracht. Maar bij de ontwikkeling van geneesmiddelen gaat het om de balans tussen effectiviteit en bijwerkingen: een cholesterol verlagend middel mag natuurlijk niet veel bijwerkingen hebben, maar voor geneesmiddelen tegen ernstige en dodelijke ziekten zijn soms flinke bijwerkingen acceptabel. Regelgevers lijken eerder bezig met het vermijden van alle eventuele bijverschijnselen dan met de positieve effecten. Als gevolg hiervan worden nog geen tien werkelijk innovatieve medicijnen per jaar in Europa en Amerika goedgekeurd. Als ontwikkelaars van mobiele telefoons net zo hadden gereageerd op de geruchten dat hun producten hersentumoren veroorzaken, dan was vernieuwing in die branche stilgevallen om te wachten op het ultieme bewijs dat mobieltjes veilig zijn. Onnodig duur Wij stellen de huidige toelatingsprocedure ter discussie, waarbij een positieve fase-II studie gevolgd moet worden door dure en langdurige fase-III studies, voordat een licentie afgegeven kan worden. Deze eis vertraagt de ontwikkeling van innovatieve medicijnen ernstig en maakt de ontwikkeling van innovatieve medicijnen het exclusieve terrein van een handvol grote farmaceutische bedrijven. Die kostbare trajecten maken medicijnen onnodig duur en laat beschikbaar voor patiënten. De gemiddelde kosten voor het ontwikkelen van een medicijn liggen nu op 1 miljard dollar. Wij vinden dat het wikken en wegen van risico’s en voordelen niet uitsluitend in handen van de regelgevers mag liggen. Natuurlijk hebben zij professioneel advies nodig, maar patiënten met ernstige aandoeningen kunnen vaak even goed of zelfs beter geïnformeerd zijn dan de regelgevers die beslissen over de beschikbaarheid van dergelijke medicijnen. Pogingen om het EMA, het Europese regelgevend instituut, te reorganiseren, lopen vast in stroperige bureaucratie. Patiënten, instellingen en bedrijfsleven zijn hierbij onvoldoende betrokken. Patiënten verdienen een radicale herziening van het huidige regelgevende proces. Ze verdienen vergoedingsgaranties voor nieuwe medicijnen. mytomorrows.com/blog/regels-frustrere...
Makelaar in medicijnen (Dutch) April 28, 2015 Een nieuw medicijn ontwikkelen, duurt vijftien jaar en kost een miljard euro. De eerste pilletjes zijn peperduur. Maar dat hoeft niet. Het kan goedkoper en sneller. Alleen loopt de farmaceutische industrie hopeloos achter als je dat vergelijkt met moderne technologieën als de iPhone. Ronald Brus zet met myTomorrows een breekijzer in de medicijnkast. Ronald Brus is arts en voormalig CEO van het Leidse biotechnologiebedrijf Crucell. Bij de verkoop van Crucell aan het Amerikaanse Johnson and Johnson maakte hij zijn miljoenen waarmee hij nu onbereikbare medicijnen bereikbaar maakt in myTomorrows. Inmiddels met steun van – volgens Brus – ’de beste Europese durfinvesteerders’ als Balderton Capital en Sofinnova Partners. ,,Toen mijn vader longkanker kreeg, kwam ik er achter dat veel dingen beter kunnen. Ik ontdekte als arts – en werkzaam midden in de wereld van de farmacie – dat het bijna onmogelijk was om voor hem de nieuwste medicijnen te krijgen. Dat kan niet de bedoeling zijn, dus ging ik kijken hoe het systeem werkt. Ik ontdekte dat de weg van reageerbuis naar patiënt veel te lang duurt.’’ Marktplaats Met de huidige stand van de technologie kan dat anders. ,,De wetgeving is fair en biedt ruimte voor ’compassionate use’ (het bij wijze van uitzondering voorschrijven van niet-geregistreerde geneesmiddelen) voor schrijnende gevallen. Maar een arts kan niet eenvoudig aankloppen bij een bedrijf met een medicijn dat nog in experimentfase verkeert. Wij creëren met myTomorrows een soort marktplaats van firma’s die willen meewerken. We houden ons volledig aan de wet. De aanvragen van artsen zijn over het algemeen zo goed onderbouwd dat de inspectie ook toestemming geeft.’’ Wereldwijd Zijn eerste 2,5 miljoen euro in myTomorrows ging op aan het onderzoeken en het begrijpen van alle juridische systemen op farmaceutisch gebied. Wereldwijd. myTomorrows is actief in heel Europa en heeft inmiddels ook voet aan de grond in Amerika waar de ’right to try’-beweging opkomt voor mensen die experimentele medicijnen willen gebruiken. ,,Nu weten we hoe het moet. Het begint met een deal sluiten met een farmabedrijf zodat artsen bij ons in de winkel kunnen kijken of we wat nieuws voor hun gereedschapskist hebben. En ze weten dan zeker dat ze het ook geleverd kunnen krijgen. Ons model is niet veel anders dan marktplaats of makelaar in medicijnen. Wij maken het mogelijk. We zijn geen patiënten aan het overhalen, we maken geen reclame. Dat mag niet eens. Alles gebeurt via de arts en dat moet ook zo blijven.’’ Gereedschapskist Inmiddels heeft de gereedschapskist van myTomorrows zeven experimentele medicijnen. Het bedrijf richt zich op middelen die worden ingezet bij oncologie, ernstige depressie, aandoeningen aan het centraal zenuwstelsel, alzheimer, MS en ALS. Brus hoopt dat hierdoor het roer om gaat in medicijnland. ,,Er komen politieke en maatschappelijke discussies omdat wij die medicijnen aanbieden. Dat gaat werken. Ik voel me geen Messias als ik dat zeg, maar als er straks weer een zoon is met een vader met kanker, vind ik dat ze een betere keuze moeten hebben en hoop ik dat de dokter de grootste gereedschapskist heeft die er is.’’ Alles in de wereld gaat sneller, behalve medicijnontwikkeling. Als het aan Brus ligt wordt er een tandje bij gezet. Voor we een medicijn aan mensen mogen geven, moet het goed zijn onderzocht in laboratoria en getest met dierproeven. ,,Dat heeft alles te maken met het medicijn Softenon tegen ochtendmisselijkheid bij zwangere vrouwen. Dat veroorzaakte in de jaren zestig misvormde kinderen. Daarom zijn er nu drie fases met veldproeven. In 1960 duurde hetzelfde proces drie tot zes jaar.’’mytomorrows.com/blog/makelaar-in-medi...
’right to try’-beweging. Interessante artikelen flosz! Wederom dank voor het delen.
wim brands...boeken...vpro: Joris Luyendijk Te gast is Joris Luyendijk. Hij kreeg van The Guardian de opdracht om te schrijven over The City, het financiële hart van Groot-Brittannië. Het resultaat is het boek 'Dit kan niet waar zijn'.Meer
Health~Holland Knowledge & Innovation Agenda www.health-holland.com/public/downloa...
List in Europe or the U.S..... Zie bijlage. Art.via:twitter.com/amitkjolly/status/6108794...
Top European Ipo's 2014: ArGen-X, ProQR, $QURE
Totaal OT: Gisteravond docu.film Keep On Keepin' On gezien (Via Uur vd Wolf,Ned.2). Leven en vriendschap tussen Jazz-trompettist Clark Terry en Pianist Justin Kauflin, prachtig imho.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
910,59
+0,71%
EUR/USD
1,0771
0,00%
FTSE 100
8.433,76
+0,63%
Germany40^
18.773,50
+0,47%
Gold spot
2.360,72
0,00%
NY-Nasdaq Composite
16.340,87
-0,03%
Stijgers
Dalers